News

Gene TherapiesR&D project spotlight: Towards continuous manufacturing for high-dose, cost-efficient rAAV therapies
Filter:AllPress ReleaseCell TherapiesGene TherapiesDigital and AutomationSpin-outs, Start-ups, Sector investmentManufacturingRegulatory affairsSkills and Training
Year:All2025202420232022 →
Frameworks for promising therapies with less mature evidence base to secure adoptionFrameworks for promising therapies with less mature evidence base to secure adoptionCell and Gene Therapy Catapult appoints three new Non-Executive Directors to the BoardCell and Gene Therapy Catapult appoints three new Non-Executive Directors to the BoardCell Therapy Catapult is now the Cell and Gene Therapy CatapultCell Therapy Catapult is now the Cell and Gene Therapy CatapultHorizon 2020 awards €6.8m to TETRA consortium for pivotal replacement trachea trialHorizon 2020 awards €6.8m to TETRA consortium for pivotal replacement trachea trialCell Therapy Catapult details key milestones and achievements in 2015 Annual ReviewCell Therapy Catapult details key milestones and achievements in 2015 Annual ReviewCell Therapy Catapult signs Memorandum of Understanding with Kanagawa Prefecture, JapanCell Therapy Catapult signs Memorandum of Understanding with Kanagawa Prefecture, JapanBIA publishes briefing paper on ATMPs and regenerative medicineBIA publishes briefing paper on ATMPs and regenerative medicineEMA releases new guidance on methods to be used in the design and conduct of post-authorisation efficacy studiesEMA releases new guidance on methods to be used in the design and conduct of post-authorisation efficacy studiesConstruction initiated on Cell Therapy Catapult’s £55 million cell and gene therapy manufacturing centreConstruction initiated on Cell Therapy Catapult’s £55 million cell and gene therapy manufacturing centreUS Guidance for Industry updateUS Guidance for Industry updateEMA implements new system for better reporting of suspected adverse reactions to medicines via EudraVigilanceEMA implements new system for better reporting of suspected adverse reactions to medicines via EudraVigilanceEMA continues its efforts to facilitate early patient access to innovative medicines through initiation of PRIME schemeEMA continues its efforts to facilitate early patient access to innovative medicines through initiation of PRIME scheme